SEC Company Response from Lantern Pharma Inc. (LTRN) (CIK 0001763950) (LTRN) — Jan 11, 2021
Lantern Pharma Inc. (LTRN) (CIK 0001763950)
Date: Jan. 11, 2021 · CIK: 0001763950 · Accession: 0001213900-21-001391
AI Filing Summary & Sentiment
Show Raw Text
CORRESP
1
filename1.htm
ThinkEquity
A division of Fordham Financial
Management, Inc.
17 State Street,
22nd Floor
New York, NY 10004
January
11, 2021
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporate Finance
100 F St., NE
Washington, D.C. 20549
Re: Lantern Pharma Inc.
Registration
Statement on Form S-1
Ladies and Gentlemen:
Pursuant
to Rule 461 of the General Rules and Regulations of the U.S. Securities and Exchange Commission under the Securities Act of 1933,
as amended, ThinkEquity, a division of Fordham Financial Management, Inc., as representative of the underwriters, hereby requests
acceleration of the effective date of the above-referenced Registration Statement so that it will become effective at 5:00 p.m.
Eastern Time on Wednesday, January 13, 2021, or as soon thereafter as practicable.
Pursuant
to Rule 460 under the Securities Act, please be advised that there will be distributed to each underwriter, who is reasonably anticipated
to be invited to participate in the distribution of the security, as many copies of the proposed form of preliminary prospectus
as appears to be reasonable to secure adequate distribution of the preliminary prospectus.
The
undersigned confirms that it has complied with and will continue to comply with, and it has been informed or will be informed by
participating dealers that they have complied with or will comply with, Rule 15c2-8 promulgated under the Securities Exchange Act
of 1934, as amended, in connection with the above-referenced issue.
Very truly yours,
ThinkEquity
A division of Fordham Financial Management, Inc.
By:
/s/ Eric Lord
Name:
Eric Lord
Title:
Head of Investment Banking